Treating cold sores with anti-virals ‘may slash risk of developing Alzheimer's'
Previous studies have found that the herpes simplex virus type 1 (HSV-1) can lie dormant in human cells for a lifetime before 're-awakening', leading to dementia symptoms.
Experts have discovered that HSV-1 causes changes that resemble those in the brains of dementia patients, such as amyloid plaque-like formations and inflammation.
Now, a large US study suggests that treating HSV-1 may be a route to lessening the risk of Alzheimer's disease.
Researchers, including from pharmaceutical firm Gilead Sciences and the University of Washington in Seattle, used data on 344,628 people with Alzheimer's matched with the same number of people without the disease.
All were aged over 50 and the diagnosis of Alzheimer's was made between 2006 and 2021.
A history of HSV-1 diagnosis was noted for 1,507 (0.44%) patients with Alzheimer's, compared with 823 (0.24%) of those without.
Nearly two thirds (65%) of those with Alzheimer's disease were women, with an average age if 73.
The study found that people who had suffered the herpes virus had an 80% increased risk of Alzheimer's, even when other factors were taken into account.
But those with HSV-1 who used anti-virals to treat the virus were 17% less likely to develop Alzheimer's compared with those who did not the medicines.
Among the 2,330 people with a history of HSV-1 infection, 931 (40%) used anti-virals after their diagnosis.
The authors, writing in the journal BMJ Open, concluded: 'Findings from this large…study implicate HSV-1 in the development of Alzheimer's disease and highlight anti-herpetic therapies as potentially protective for Alzheimer's and related dementia.'
In the UK, the drug aciclovir is one of those available for treating cold sores, chickenpox, shingles and other herpes virus infections.
The researchers also looked at the potential role of other herpes viruses, including HSV-2, varicella zoster virus (which causes chickenpox), and cytomegalovirus.
Both HSV-2 and varicella zoster virus infections were also associated with a heightened risk of Alzheimer's disease.
Exactly how HSV-1 and other viruses might heighten the risk of dementia is not clear, point out the researchers.
'However, studies have shown that inflammatory alterations in the brain caused by HSV infection are pivotal in (Alzheimer's disease) development,' they added.
HSV-1 DNA is also found in the plaques characteristic of Alzheimer's disease, and people carrying the most common genetic risk factor for the disease are more susceptible to HSV infections, they said.
Professor Tara Spires-Jones, from the University of Edinburgh, said: 'This is a well-conducted study adding to strong data in the field linking HSV-1 and other viral infections to increased risk of developing Alzheimer's disease, but it is important to note that HSV-1 infection, which is extremely common in the population, is by no means a guarantee that someone will develop Alzheimer's.
'Why viral infections may increase risk of dementia is not fully understood, but the most likely explanation is that infections increase inflammation in the body and contribute to age-related brain inflammation.
'More research is needed to understand the best way to protect our brains from Alzheimer's disease as we age, including a better understanding of links between viral infection and Alzheimer's risk.'
Dr David Vickers, from the University of Calgary in Canada, said the 'research exaggerates the role of HSV-1, failing to appreciate its absence in 99.56% of Alzheimer's disease cases'.
He added: 'The observed 17% hazard reduction with anti-herpetic drugs translates to a mere nine-month delay in Alzheimer's disease onset.'
Dr Richard Oakley, director of research and innovation at the Alzheimer's Society, said: 'Results from this observational study suggested that people with recorded cold sore infections were more likely to develop Alzheimer's disease, and interestingly those prescribed antiviral drugs had a slightly lower risk.
'But this doesn't prove that cold sores cause Alzheimer's disease, or that anti-virals prevent it.
'The data came from insurance records, often based on self-reported symptoms which may miss or misclassify infections, and didn't track how often people had cold sores or how consistently they took medication.
'Much more research is needed to explore exactly how viruses might be involved and before we can draw firm conclusions.'
Dr Sheona Scales, director of research at Alzheimer's Research UK, welcomed the study but said more research was needed.
'We know there are 14 established risk factors for dementia, and there's not enough evidence to include infections in this list.
'This study doesn't tell us if infections are causing the risk, it only shows an association. Further research is needed to understand what the underlying biology around this is.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South Wales Guardian
5 hours ago
- South Wales Guardian
6 things you need to know about Alzheimer's – as drug trials bring new hope
Led by an expert from the University of Nevada in the US and published in the journal Alzheimer's & Dementia: Translational Research and Clinical Interventions, the review reveals that 182 clinical trials are underway in 2025, a rise of 11% from the previous year, assessing the impact 138 potential drugs. Notably, one-third of these drugs are repurposed medications originally developed for other conditions like diabetes, multiple sclerosis, and high cholesterol. A post shared by Alzheimer's Research UK (@alzheimersresearchuk) 1. Alzheimer's and dementia are not the same thing 'A lot of people get confused between Alzheimer's and dementia and aren't really sure what the difference is,' recognises Taylor. 'The way I describe it is that dementia is the group of symptoms – so things like memory loss, confusion, personality and behavioural changes – and Alzheimer's is one of the causes of those symptoms.' Research generally associates Alzheimer's disease with the accumulation of two proteins, amyloid and tau, says Taylor. 'These toxic proteins damage our brain cells, which are what is used to communicate messages throughout our body,' she explains. 'Overtime, as more brain cells die, it becomes harder for our brain overall to carry out its normal functions. So, depending on where in the brain the damage starts, that indicates what kind of symptoms someone will experience. 'That's why in Alzheimer's early symptoms are often memory loss and confusion because Alzheimer's tends to, but doesn't always, start in the memory centres of the brain.' 2. There are 14 potential risk factors 'A lot of the risk factors for dementia are linked to our heart health,' says Taylor. 'So, we know that what's good for your heart is good for your brain as well. 'Things like having a healthy diet, exercising regularly, limiting the amount of alcohol you drink, not smoking, keeping your blood pressure and cholesterol under control etc is really important to improve or maintain our brain health and reduce our risk of dementia. 'These risk factors, there are 14 in total, have been linked to 45% of dementia cases worldwide. So, if those risk factors were completely eliminated, then up to 45% would be prevented or delayed.'3. It isn't an inevitable part of ageing 'A lot of people think it's an inevitable part of ageing, but it's definitely not – we can do things to reduce our risk of dementia,' says Taylor. While Alzheimer's disease is more common in older adults, it can also affect younger people. 'People as young as 30 have developed Alzheimer's and obviously that is quite rare, but it really does show that it's not just a part of ageing,' says Taylor. 'It's a biological disease and if something goes wrong, then we can try and find a way to make it right – that's where research comes in.' 4. It isn't just about memory loss 'I think a lot of people just think of Alzheimer's as memory loss, but it can affect a lot of different aspects of someone's memory and thinking,' highlights Taylor. 'Someone might become very confused and might not be sure of the time or the date, they might misplace things a lot or put them in odd places, like putting a TV remote in the fridge.' Alzheimer's can also really affect language skills. 'People might have problems finding the right words or understanding the meaning of words or might struggle to follow conversations, and that might mean that they become quite withdrawn,' says Taylor. In addition, there's a lot of links between Alzheimer's and mood and behaviour changes. 'People can become low in mood. other people may become more agitated or aggressive, and that's a really heartbreaking thing for someone to go through,' says Taylor. A post shared by Alzheimer's Research UK (@alzheimersresearchuk) 'People often ring us and say why would I bother going to the doctor if there's no cure yet – but I think the benefits of getting a diagnosis is that support and understanding that you get from knowing what's going on, and the ability to plan ahead,' says Taylor. 'Getting a diagnosis means you can put things in place like the lasting power of attorney and sort out your will and finances while you have time. 'Getting an early diagnosis also means getting those treatments while they're likely to work best, and a diagnosis also provides more opportunities to take part in research, so the future generations don't have to go through the same thing.' 6. Remember to be patient with loved ones who have Alzheimer's 'Someone might change quite a lot when they have Alzheimer's, but it doesn't mean that they deep down aren't the same person,' emphasises Taylor. 'Someone's behaviour might change quite drastically throughout the course of the disease but it's not coming from a bad place. 'So, patience and understanding is really key when dealing with anyone with any form of dementia. Treasure the time that you have with them.'For more information about dementia, dementia research or taking part in research, visit Alzheimer's Research UK's website or contact its Dementia Research Infoline on 0300 111 5111 or email infoline@
NBC News
7 hours ago
- NBC News
Wegovy use among U.S. teens up 50% as obesity crisis worsens
American teens are increasingly turning to the weight-loss drug Wegovy as more families and their doctors gain confidence in its use for young people with obesity, new data shared with Reuters shows. The average rate of teens beginning treatment with the highly effective Novo Nordisk drug grew 50% last year to 14.8 prescriptions per 100,000 adolescents, according to an analysis by health data firm Truveta. That's up from a rate of 9.9 prescriptions per 100,000 in 2023, the first full year that Wegovy was available to children aged 12 and older. The average rate climbed further during the first three months of this year, reaching 17.3 new prescriptions per 100,000. That still represents a minute fraction of the estimated 23,000 out of every 100,000 teens in the country who are living with obesity, and is far slower than the uptake among U.S. adults. 'It's promising that more young people are using these medications, but it's still a very small percentage of patients with severe obesity that are getting access to them,' said Dr. Cate Varney, director of obesity medicine at the University of Virginia Health system. 'When lifestyle changes alone are insufficient, we need these additional tools.' For its analysis, Truveta reviewed the electronic health records of 1.3 million patients ages 12 through 17. The data covers 30 U.S. health systems with more than 900 hospitals and 20,000 clinics across the country. The analysis did not include other GLP-1 drugs, including Novo's Ozempic and Eli Lilly's LLY.N Zepbound, which are not approved to treat obesity in adolescents, or compounded versions of these therapies. Wegovy became an option to treat adolescents in late 2022 after decades in which the conventional approaches of diet, exercise and counseling largely failed. About 8 million American teens, or 23% of people ages 12 to 19, have obesity, up from 5% in 1980, according to U.S. government data. Young people with obesity run a much higher risk of developing chronic, costly, life-shortening conditions like type 2 diabetes and cardiovascular and liver diseases. In January 2023, the American Academy of Pediatrics strongly recommended that doctors provide weight-loss drugs to children with obesity starting at age 12. Yet the medical community has not uniformly embraced GLP-1s for adolescents. Some doctors are hesitant because the drugs' long-term safety for children during a critical phase of development is unknown, and the treatments may need to be used indefinitely. Overall, there are limited options for many teens and their parents because insurance plans often do not cover any treatment for obesity, including intensive behavioral counseling, visits with a dietician or the new GLP-1 medications. At Nemours Children's Hospital in Wilmington, Delaware, the Healthy Weight and Wellness Clinic treated about 2,000 adolescent patients last year. About 25% were prescribed Wegovy or another GLP-1 medication, said Dr. Thao-Ly Phan, the clinic's medical director. The number of adolescents with a GLP-1 prescription nearly doubled from 2023. On average, their patients taking a GLP-1 drug lost 15 pounds (6.8 kg) within 6 to 12 months, and nearly 30 pounds after more than a year. For many of the other patients, the medications were not an option, either because of insurance hurdles or concern within families about potential risks. Other teens opted for lifestyle changes or older, cheaper weight-loss drugs, with some success. 'It is important for us to continue to monitor and better understand outcomes from the medications — both positive and negative — before widespread use,' Phan said. U.S. Health Secretary Robert F. Kennedy Jr. has criticized the idea of prescribing Ozempic or Wegovy widely to children to treat obesity. In a federal health report he released last month, GLP-1 drugs were cited as an example of the 'overmedicalization of our kids.' It noted a lack of 'long-term safety data, raising the specter of unforeseen problems that interrupt, damage, or impair metabolism and growth development.' Novo in a statement said semaglutide, the active ingredient in Wegovy and Ozempic, 'did not appear to affect growth or pubertal development' during its clinical trials involving teens. For many adults, Novo said, obesity starts in childhood or adolescence, and 'we are confident in the proven safety and efficacy of our GLP-1 medicines.' Eli Lilly's weight-loss drug Zepbound is in late-stage clinical trials for use by adolescents. Lilly told Reuters that 'there has been no evidence to date suggesting impairment in growth or metabolism' from GLP-1 medications. Dr. Robert Siegel, a pediatrician and director of the Center for Better Health and Nutrition at Cincinnati Children's Hospital, said about 15% of adolescents being treated there were prescribed Wegovy or a similar GLP-1 medication from July 2021 to July 2023. They include patients being treated for type 2 diabetes for which the GLP-1 drugs were originally developed. Siegel said he prefers to start teens on three to six months of intensive lifestyle management before even considering medication. While obesity specialists can help navigate potential risks from the drugs, many primary-care providers need more training, he said. They may not have the equipment to monitor for the loss of muscle mass — a side effect of these medicines — or lack the resources to work with families over an extended period on healthier eating and exercise. 'These medications are likely to be needed for a very long time to maintain weight,' Siegel said, 'and we only have a relatively short-term experience with them.'
Economist
8 hours ago
- Economist
The Alzheimer's drug pipeline is healthier than you might think
OF ALL THE medical challenges that scientists have faced, Alzheimer's disease, the most common form of dementia, has been one of the trickiest. Between 1995 and 2021 private money spent on Alzheimer's research totalled $42.5bn, but more than 140 trials failed to deliver a single drug capable of slowing the disease. Yet the tide may be turning. There are two working drugs, offering modest benefits, on the market. A new review paper suggests more could soon follow.
